

3-2017

# Neurotensin NTS1 and NTS2 receptor agonists produce anxiolytic-like effects in the 22-kHz ultrasonic vocalization model in rats

Floyd F. Steele III

*Virginia Commonwealth University, fsteel@vcu.edu*

Shannon C. Whitehouse

*Northern Michigan University, swhiteho@nmu.edu*


Jacob S. Aday

*Northern Michigan University, jaday@nmu.edu*

Adam J. Prus

*Northern Michigan University, aprus@nmu.edu*

Follow this and additional works at: [http://commons.nmu.edu/facwork\\_journalarticles](http://commons.nmu.edu/facwork_journalarticles)

 Part of the [Behavioral Neurobiology Commons](#), [Biological Psychology Commons](#), [Medicinal Chemistry and Pharmaceutics Commons](#), [Pharmacology Commons](#), and the [Systems Neuroscience Commons](#)

---

## Recommended Citation

Steele, Floyd F. III; Whitehouse, Shannon C.; Aday, Jacob S.; and Prus, Adam J., "Neurotensin NTS1 and NTS2 receptor agonists produce anxiolytic-like effects in the 22-kHz ultrasonic vocalization model in rats" (2017). *Journal Articles*. 353.  
[http://commons.nmu.edu/facwork\\_journalarticles/353](http://commons.nmu.edu/facwork_journalarticles/353)

This Journal Article is brought to you for free and open access by NMU Commons. It has been accepted for inclusion in Journal Articles by an authorized administrator of NMU Commons. For more information, please contact [kmcdonou@nmu.edu](mailto:kmcdonou@nmu.edu), [bsarjean@nmu.edu](mailto:bsarjean@nmu.edu).

RUNNING HEAD: Neurotensin reduces 22-kHz USVs

Neurotensin NTS<sub>1</sub> and NTS<sub>2</sub> receptor agonists produce anxiolytic-like effects in the 22-kHz  
ultrasonic vocalization model in rats

Floyd F. Steele III<sup>1</sup>, Shannon C. Whitehouse<sup>2</sup>, Jacob S. Aday<sup>2</sup>, and Adam J. Prus<sup>2\*</sup>

1-Department of Pharmacology and Toxicology, Virginia Commonwealth University,  
Richmond, VA

2-Psychology Department, Northern Michigan University, Marquette, MI

\*Corresponding author

Adam J. Prus, Ph.D.  
Psychology Department  
Northern Michigan University  
Marquette, MI 49855  
p. 906-227-2941  
f. 906-227-2954  
e. aprus@nmu.edu

Abbreviations: ultrasonic vocalizations (USV); basolateral amygdala (BLA); central nucleus of  
the amygdala (CeA)

This is the accepted manuscript version. The actual published version  
may include changes. Please do not reference this article without  
permission from the author. The final version is available at 10.1016/  
j.brainres.2017.01.012

## ABSTRACT

Neurotensin is a neuropeptide neurotransmitter that interacts with multiple neurotransmitter systems, including those regulating amygdalar function, via NTS<sub>1</sub> and NTS<sub>2</sub> receptors. Both receptors are expressed in the amygdala and agonists for NTS<sub>1</sub> or NTS<sub>2</sub> receptors have exhibited anxiolytic effects in animal models. Systemic administration of NTS<sub>1</sub> receptor agonist PD149163 was recently shown to reduce footshock conditioned 22-kHz ultrasonic vocalizations in rats, suggesting that PD149163 produced an anxiolytic effect. The effects that neurotensin may have or a selective NTS<sub>2</sub> receptor agonist may have on 22-kHz vocalizations has yet to be examined. The current study evaluated the effects of intracerebroventricularly administered neurotensin (0.1 - 10.0 μg), PD149163 (0.1-10.0 ng), or the NTS<sub>2</sub> receptor agonist JMV-431 (0.1 - 1.0 μg) on footshock conditioned 22-kHz vocalizations in male Wistar rats. Neurotensin, PD149163, and JMV-431 all significantly reduced the number 22-kHz calls. No changes in call duration were found, suggesting that non-specific drug effects do not account for the reductions in 22-kHz calls. These data support anxiolytic effects produced by activation of NTS<sub>1</sub> or NTS<sub>2</sub> receptors, and suggest that neurotensin plays a natural role in the expression of conditioned USVs. These data suggest that both receptor subtypes are putative pharmacologic targets.

**Keywords:** anxiety; ultrasonic vocalization; neurotensin; NTS<sub>1</sub> receptor; NTS<sub>2</sub> receptor

## 1. Introduction

Neurotensin is a neuropeptide neurotransmitter distributed throughout much of the CNS and that interacts with a number of neurotransmitter systems through NTS<sub>1</sub> or NTS<sub>2</sub> receptors (Kleczkowska and Lipkowski, 2013; Vincent et al., 1999). Soon after its discovery by Carraway and Leeman (Carraway and Leeman, 1973), studies found that intracranial administration of neurotensin produced some physiological and behavioral effects similar to those produced by antipsychotic drugs (Jolicoeur et al., 1993; Nemeroff, 1980). These findings formed the basis for developing a number of synthetic neurotensin analogs capable of crossing the blood-brain barrier, such as NT69L (Tyler et al., 1999) and PD149163 (Wustrow et al., 1995).

There is an emerging line of research examining the role of neurotensin in anxiety and the potential of neurotensin receptor agonists to treat anxiety disorders. In post traumatic stress disorder, Maes et al. (1999) reported high levels of prolyl endopeptidase, a degradation enzyme of neurotensin, in blood plasma, suggesting lower levels of neurotensin in these patients (Maes et al., 1999). Corresponding with these findings, Ruiz et al. (1992) found lower levels of neurotensin in blood plasma of those with either an anxiety disorder or depression, which were raised upon recovery. Both NTS<sub>1</sub> and NTS<sub>2</sub> receptors are also found in the amygdala, including basolateral amygdala and central nucleus (Boudin et al., 1996; Lantos et al., 1996; Sarret et al., 2003).

An early suggestion that neurotensin might exhibit anxiolytic-like effects was demonstrated by Elliot et al. (1986) who found that intracranial neurotensin administration led rats to spend more time in the center versus the perimeter of an open field. Shilling & Feifel (2008) found that the highly selective NTS<sub>1</sub> receptor agonist PD149163 (Petrie et al., 2004;

1  
2  
3  
4 Table 1) attenuated fear-potentiated startle in rats. The peptide  $\beta$ -lactotensin, which has a  
5  
6 preferential affinity as an agonist for NTS<sub>2</sub> receptors over NTS<sub>1</sub> receptors (Yamauchi et al.,  
7  
8 2003), has also been shown to weaken fear conditioning and attenuate the effects of restraint  
9  
10 stress measured during a hole-board test (Yamauchi et al., 2006), increase the time spent in open  
11  
12 elevated plus maze arms, and time spent in the center of an open field (Hou et al., 2011).  
13  
14

15  
16 A model becoming increasingly used to screen anxiolytic drugs is the footshock  
17  
18 conditioned 22-kHz ultrasonic vocalization (USV) model in rats (Molewijk et al., 1995; Sánchez,  
19  
20 2003; Simola, 2015). Calls at this frequency are produced when rats are confronted with natural  
21  
22 predators (Brudzynski, 2015) and increase as the distance to a predator decreases (Litvin,  
23  
24 Blanchard, & Blanchard, 2007). Audio playback of rat 22-kHz calls to non-conditioned rats  
25  
26 produces increased c-fos activity in brain regions associated with fear conditioning, such as the  
27  
28 amygdala and periaqueductal grey area. These calls also correlate with defensive behaviors such  
29  
30 as conditioned freezing and staying in the closed arms of an elevated plus maze (Borta et al.,  
31  
32 2006). In a previous study from this laboratory, Prus et al. (2014) demonstrated that PD149163  
33  
34 significantly reduced footshock conditioned 22-kHz USVs in rats, which was a result typical of  
35  
36 anxiolytic drugs such as the 5-HT<sub>1A</sub> partial agonist buspirone (Molewijk et al., 1995; Prus et al.,  
37  
38 2014) and some benzodiazepines (Molewijk et al., 1995). Chou et al. (2015) measured 22-kHz  
39  
40 USVs in rats performing a conditioned avoidance response task, and in these animals, PD149163  
41  
42 also reduced 22-kHz USVs.  
43  
44  
45  
46  
47  
48  
49

50  
51 The aim of the current study was to add to past findings on the effects of neurotensin  
52  
53 ligands on anxiety by testing the CNS effects of PD149163, neurotensin and the NTS<sub>2</sub> receptor  
54  
55 agonist Boc- $[\Psi$ 11,12]NT(8-13) (JMV-431) (Dubuc et al., 1999; Richard et al., 2001; Table 1) in  
56  
57 the conditioned foot-shock induced 22-kHz USV model. Past findings have shown PD149163 to  
58  
59  
60  
61  
62  
63  
64  
65

1  
2  
3  
4 reduce USVs in this model, but an assessment of neurotensin has not been evaluated. Studies  
5  
6 have yet to be conducted using a selective NTS<sub>2</sub> receptor agonist in this model. In order to  
7  
8 closely compare the effects of these selective ligands with neurotensin, which does not cross the  
9  
10 blood-brain barrier, all compounds were microinjected into the lateral ventricle.  
11  
12

## 13 14 **2. Results**

15  
16 Animals that did not emit at least 80 vocalizations during a test after conditioning were  
17  
18 eliminated prior to surgery and data were removed for rats with incorrect cannula placements.  
19  
20 Based on this, data were analyzed from 19 rats [PD149169 (N=7), JMV-431 (N=7) and NT  
21  
22 (N=5)]. There was not a statistically significant difference ( $p > 0.05$ ) between the first and  
23  
24 second vehicle assessments on the number of USV calls for either neurotensin [ $t(4)=0.95$ ,  $p >$   
25  
26  $0.05$ ], PD149163 [ $t(6)=0.12$ ,  $p > 0.05$ ], or JMV-431 [ $t(6)=0.02$ ,  $p > 0.05$ ]; moreover, the vehicle  
27  
28 data for neurotensin, PD149163 or JMV-431 did not differ significantly between these groups,  
29  
30  $F(2, 16) = 1.13$ ,  $p > 0.05$ . Neurotensin (0.1, 1.0, and 10.0 $\mu$ g) significantly reduced the number of  
31  
32 USV calls,  $F(3,12) = 6.69$ ,  $p < 0.05$ , and post hoc testing found significantly fewer calls for only  
33  
34 10  $\mu$ g of neurotensin compared to vehicle (figure 1). PD149163 (0.1, 1.0, & 10.0 ng) also  
35  
36 significantly reduced USV calls,  $F(3,18) = 17.33$ ,  $p < 0.001$ , which occurred as a reduction in  
37  
38 calls following administration of 10 ng of PD149163 compared to vehicle (figure 2, top panel).  
39  
40 JMV-431 (0.1 and 1.0 $\mu$ g) significantly reduced the number of calls  $F(2,12) = 19.08$ ,  $p < 0.001$ ,  
41  
42 following administration of 1.0 $\mu$ g compared to vehicle (figure 2, bottom panel).  
43  
44  
45  
46  
47  
48  
49

50  
51 There was not a significant difference between the USV call durations of the first and  
52  
53 second vehicle tests for any of the drugs evaluated (data not shown), nor did USV call durations  
54  
55 for vehicle differ between the treatment groups. None of the compounds tested produced  
56  
57 statistical differences in USV call duration (all  $p$  values  $> 0.05$ , see Table 2).  
58  
59  
60  
61  
62  
63  
64  
65

### 3. Discussion

In the present study, intracerebroventricular administration of the neuropeptide neurotensin, the selective NTS<sub>1</sub> receptor agonist PD149163, and the selective NTS<sub>2</sub> receptor agonist JMV-431 produced a significant reduction in footshock conditioned 22-kHz USV calls in rats, an effect considered predictive of anxiolytic efficacy (e.g., Molewijk et al., 1995; Simola, 2015). These reductions were shown for the “long” type of 22-kHz USVs (approx. 1s), which are the length of calls emitted from rats presented with threatening stimuli (Simola, 2015). As addressed in the introduction, several past studies suggest an anxiolytic profile for neurotensin and a role for anxiolytic effects via activation of NTS<sub>1</sub> or NTS<sub>2</sub> receptors. In particular, a past study in this laboratory found that systemic administration of PD149163 significantly reduced 22-kHz USVs using procedures similar to those in the present study (Prus et al., 2014). In the present study, PD149163 was 1,000 fold more potent than neurotensin (0.01 vs 10.0 ug, respectively) and 100 fold more potent than JMV-431 (1.0 ug) in reducing the number of 22-kHz calls emitted. Graded dose response curves were not shown for these compounds, likely due to using 10-fold differences between each dose.

Brain neurotensin systems may have specific relationships with mechanisms mediating conditioned 22-kHz USV production, but it seems more likely that neurotensin and neurotensin receptor agonists reduce 22-kHz USVs by acting to reduce anxiety. Numerous pharmacological studies link cholinergic activity and cholinergic muscarinic receptor activation to the production of 22-kHz USVs (for review see Brudzynski, 2015); neurotensin’s interactions with cholinergic systems (Szigethy et al., 1988) enhances the activity of cholinergic neurons (Alonso et al., 1994; Gully et al., 1997) leading to acetylcholine efflux (e.g., Gully et al., 1997; Kitabgi and Freychet, 1979; Lapchak et al., 1991; Prus et al., 2007; Rakovska et al., 1998). Thus, from these actions

1  
2  
3  
4 alone, neurotensin might be predicted to enhance 22-kHz USVs, which is the opposite of what is  
5  
6 found.

7  
8  
9 Likely, the ability of neurotensin and its agonists to reduce the emission of 22-kHz USVs  
10  
11 occurs through processing and conditioning of fear responses, as has been demonstrated by  
12  
13 neurotensin, NTS<sub>1</sub> receptor agonists and NTS<sub>2</sub> receptor agonists in past studies noted earlier.  
14  
15 Dense neurotensin-containing fibers terminate in the central nucleus of the amygdala (CeA)  
16  
17 (Jennes et al., 1982), and the basolateral amygdala (BLA) and CeA contain high levels of NTS<sub>1</sub>  
18  
19 and NTS<sub>2</sub> receptors (Boudin et al., 1996; Lantos et al., 1996; Sarret et al., 2003). Neurotensin  
20  
21 receptors may alter glutamatergic neurotransmission in the amygdala, which may alter fear  
22  
23 conditioning processes. Neurotensin has been shown to facilitate NMDA-elicited increases in  
24  
25 glutamate (Ferraro et al., 2011) and NTS<sub>1</sub> receptor activation may disinhibit BLA pyramidal  
26  
27 neurons, thereby promoting long-term potentiation (Kroner et al., 2005). Beyond glutamate  
28  
29 interactions, there is evidence that neurotensin receptors interact with neurotransmitters with  
30  
31 terminals in the amygdala, including dopamine (Asan, 1998) and serotonin (Boudin et al., 1996;  
32  
33 Jolas and Aghajanian, 1996; Sarret et al., 2003).

34  
35  
36 The present study provided further evidence that neurotensin receptor mechanisms appear  
37  
38 involved in fear conditioning processes and that agonists for neurotensin receptors may be  
39  
40 pursued as novel anxiolytic drugs. Neurotensin, like the NTS<sub>1</sub> receptor agonist PD148163 in a  
41  
42 previous study (Prus et al., 2014), exhibited an attenuation on footshock-conditioned USVs,  
43  
44 suggesting that neurotensin plays a natural role in reducing anxiety. The findings with JMV-431  
45  
46 also support anxiolytic effects occurring through NTS<sub>2</sub> receptor activation. These receptors, in  
47  
48 particular, are worth pursuing as a novel pharmacologic strategy for treating anxiety as NTS<sub>1</sub>, but  
49  
50 not NTS<sub>2</sub>, receptors have been associated with malignant tumor growth in human cancer cells  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65



(Dal Farra et al., 2001). JMV-431 does not readily cross the blood-brain barrier (unpublished findings), and therefore, there is a need for highly selective and brain penetrant NTS<sub>2</sub> receptor agonists in order to assess the clinical utility of such compounds in animal models.

## **4. Experimental Procedure**

### **4.1 Subjects**

Thirty male Wistar rats (Charles River Laboratories, Portage, MI) were used in this study and housed in a temperature and humidity controlled vivarium set on a 12 hr light/dark cycle. Rats were 10-12 weeks old when experiments began. All procedures were approved by the Institutional Animal Care and Use Committee at Northern Michigan University and followed the Guide for the Care and Use of Laboratory Animals (National Research Council Committee for the Update of the Guide for the Care and Use of Laboratory Animals et al., 2011).

### **4.2 Pharmacological compounds**

The test compounds consisted of neurotensin (0.1, 1.0, & 10.0µg doses, AnaSpec, Fremont, CA, USA), PD149163 HCl (0.1, 1.0, & 10ng doses) and JMV-431 (0.1 & 1.0µg) (both generously provided by the NIMH Drug Repository, Bethesda, MD, USA). All compounds were dissolved in a phosphate buffering solution (Sigma-Aldrich, St. Louis, MO) with 1.2 mM CaCl added. The salt form of PD149163 was used.

An Equithesin solution was used for as an injectable (i.p.) surgical anesthesia for the majority of the animals; later in the study, during experiments to test JMV-431, an isoflurane vaporizer became available for gas surgical anesthesia and was used instead. An injection (s.c.) of Penicillin G (Butler Schein Animal Health, Dublin, OH, USA) was given after an animal was sedated and prior to beginning surgery. Buprenorphine (0.05 mg/kg, s.c.; Sigma Aldrich) was

1  
2  
3  
4 given twice a day as an analgesic for two days following surgery. Animals were given one week  
5  
6  
7 to recover before testing began.

#### 8 9 4.3 Apparatus and materials

10  
11 Each test compound for this study was injected into the right lateral ventricle via a  
12  
13 26 ga. guide cannulae (C315G-SPC; PlasticsOne, Roanoke, VA, USA) that was surgically  
14  
15 installed using a rodent stereotaxic device (Stoelting Co., Wood Dale, IL, USA). A matching 33  
16  
17 ga. dummy cannula (C315DC-SPC, PlasticsOne) was implanted into the guide immediately  
18  
19 following surgery and the dummy cannula was replaced by a 33 ga. injection cannula (C315I-  
20  
21 SPC, PlasticsOne) for drug injection prior to a test session. A syringe pump (MD-1001,  
22  
23 Bioanalytical Systems, Inc., Lafayette, IN, USA) injected a drug solution through an injection  
24  
25 cannula at a rate of 2 $\mu$ L per minute.  
26  
27  
28  
29  
30

31  
32 Conditioning and testing sessions were conducted using an ultrasonic vocalization  
33  
34 chamber equipped with a shock grid floor and USV detector (Med Associates, St. Albans, VT,  
35  
36 USA). Two key lights positioned at the front of the chamber were used for illumination during  
37  
38 experimental sessions. All experimental events and data recording were conducted using MED  
39  
40 PC version 4 software (Med Associates).  
41  
42

#### 43 4.4 Surgical and behavioral procedures

44  
45 Prior to the cannula implantation surgery, rats were first footshock conditioned to the  
46  
47 USV chamber and then pre-tested to determine if conditioning produced 22-kHz USVs. The pre-  
48  
49 training/testing procedures were modified from those described previously by this laboratory  
50  
51 (Prus et al., 2014). Conditioning was conducted during two consecutive daily sessions. During  
52  
53 these sessions, each rat was exposed to 6 floor grid shocks (0.8 mA, 8s duration) pseudo-  
54  
55 randomly distributed during a 7 min session. Inter-shock intervals of 27, 40, 50, 75, and 100  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

seconds were randomly selected after a shock was presented 60 seconds after the beginning of the training session. A pre-test session was conducted on the following day.

The pre-test session consisted of two trials. The first trial was 2 min long and one shock (0.8 mA, 8 s duration) was given approximately halfway through the trial. The rat was removed from the chamber at the end of this trial and then returned to the chamber 30 min later for the second trial. The second trial was 10 min long. During this trial 22-kHz USVs were recorded and no shocks were administered. Rats that failed to emit at least 80 USVs were excluded from the study prior to surgery. This training requirement was used in Molewijk et al. (1995).

A single guide cannula was installed in the right lateral ventricle at anterior/posterior = -1.0 mm, medial/lateral = +2.0 mm relative to bregma and at a depth of 2 mm from the skull surface according to stereotaxic coordinates (Paxinos and Watson, 2005) and fixed using cranioplastic cement. The injection cannula, when implanted prior to a test session, extended 2 mm beyond the tip of the guide cannula to reach the lateral ventricle. Rats were given one week to recover from surgery before testing sessions were conducted.

The testing procedure was conducted over the course of consecutive daily sessions. The first session consisted of a conditioned session as described above. The remaining sessions were test sessions as described earlier, except that the dummy cannula was replaced with an injection cannula immediately after the 2 min trial. After implanting the injection cannula, 2 $\mu$ L of drug or vehicle solution (i.e., the phosphate buffering solution) was perfused through the cannula for one minute. The syringe pump was then deactivated and remained connected to the injection cannula for an additional minute before disconnecting it. The dummy cannula was replaced after the injection cannula was removed. The 10 min test trial was conducted 30 min after the injection. For each test compound, the phosphate buffering solution vehicle was injected on the first test

1  
2  
3  
4 day and drug doses were then escalated by 10 fold for each subsequent daily test session. The  
5  
6 final test day for each compound consisted of a second administration of phosphate buffering  
7  
8 solution to assess if changes in the number of USVs occurred to baseline responding after drug  
9  
10 testing. Daily doses were increased instead of counterbalanced due to evidence of PD149163  
11  
12 producing behavioral tolerance in the USV preparation (Prus, Hillhouse, & LaCrosse, 2014).  
13  
14 Following testing, the probe placements were verified using histology and data were excluded  
15  
16 for incorrect placements.  
17  
18  
19  
20

### 21 Data Analysis

22  
23 The number and duration (s) of 22-kHz calls were reported as means (+/- standard error  
24  
25 of the mean [SEM]). As noted earlier, a vehicle test was conducted before drug testing and after  
26  
27 drug testing; a paired samples t test was subsequently conducted to determine if these before and  
28  
29 after vehicle data differed significantly. Means for each animal of the before and after tests were  
30  
31 calculated and used as the vehicle condition for subsequent analyses. A one-way repeated  
32  
33 measures analysis of variance was used to assess differences across doses and vehicle for each  
34  
35 compound. Dunnett's post hoc tests were used to compare doses to vehicle, when appropriate, at  
36  
37 the  $p < 0.05$  level. Statistical analyses were conducted using Graph Pad Prism 6 software  
38  
39 (GraphPad Software, Inc., La Jolla, CA).  
40  
41  
42  
43  
44

### 45 **References**

46  
47  
48 Alonso A, Faure MP, Beaudet A. Neurotensin promotes oscillatory bursting behavior and  
49  
50 is internalized in basal forebrain cholinergic neurons. *J Neurosci.* 1994;14:5778-92.  
51

52  
53 Asan E. The catecholaminergic innervation of the rat amygdala. *Adv Anat Embryol Cell*  
54  
55 *Biol.* 1998;142:1-118.  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1  
2  
3  
4 Borta A, Wohr M, Schwarting RK. Rat ultrasonic vocalization in aversively motivated  
5  
6 situations and the role of individual differences in anxiety-related behavior. Behavioural brain  
7  
8 research. 2006;166:271-80.  
9

10  
11 Boudin H, Pelaprat D, Rostene W, Beaudet A. Cellular distribution of neurotensin  
12  
13 receptors in rat brain: immunohistochemical study using an antipeptide antibody against the  
14  
15 cloned high affinity receptor. J Comp Neurol. 1996;373:76-89.  
16  
17

18  
19 Brudzynski SM. Pharmacology of ultrasonic vocalizations in adult rats: significance, call  
20  
21 classification and neural substrate. Curr Neuropharmacol. 2015;13:1801-192.  
22

23  
24 Carraway R, Leeman SE. The isolation of a new hypotensive peptide, neurotensin, from  
25  
26 bovine hypothalami. Journal of Biological Chemistry. 1973;248:6854-61.  
27

28  
29 Dal Farra C, Sarret P, Navarro V, Botto JM, Mazella J, Vincent JP. Involvement of the  
30  
31 neurotensin receptor subtype NTR3 in the growth effect of neurotensin on cancer cell lines. Int J  
32  
33 Cancer. 2001;92:503-9.  
34

35  
36 Dubuc I, Sarret P, Labbe-Jullie C, Botto JM, Honore E, Bourdel E, et al. Identification of  
37  
38 the receptor subtype involved in the analgesic effect of neurotensin. J Neurosci. 1999;19:503-10.  
39

40  
41 Elliott PJ, Chan J, Parker YM, Nemeroff CB. Behavioral effects of neurotensin in the  
42  
43 open field: structure-activity studies. Brain research. 1986;381:259-65.  
44

45  
46 Ferraro L, Beggiato S, Tomasini MC, Fuxe K, Tanganelli S, Antonelli T. Neurotensin  
47  
48 regulates cortical glutamate transmission by modulating N-methyl-D-aspartate receptor  
49  
50 functional activity: An in vivo microdialysis study. Journal of Neuroscience Research.  
51  
52 2011;89:1618-26.  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1  
2  
3  
4 Gully D, Labeeuw B, Boigegrain R, Oury-Donat F, Bachy A, Poncelet M, et al.

5  
6 Biochemical and pharmacological activities of SR 142948A, a new potent neurotensin receptor  
7 antagonist. *The Journal of pharmacology and experimental therapeutics*. 1997;280:802-12.  
8

9  
10  
11 Hou I, Suzuki C, Kanegawa N, Oda A, Yamada A, Yoshikawa M, et al.  $\beta$ -Lactotensin  
12 derived from bovine  $\beta$ -lactoglobulin exhibits anxiolytic-like activity as an agonist for neurotensin  
13 NTS<sub>2</sub> receptor via activation of dopamine D1 receptor in mice. *Journal of neurochemistry*.  
14 2011;119:785-90.  
15  
16

17  
18  
19 Jennes L, Stumpf WE, Kalivas PW. Neurotensin: topographical distribution in rat brain  
20 by immunohistochemistry. *J Comp Neurol*. 1982;210:211-24.  
21  
22

23  
24  
25 Jolas T, Aghajanian GK. Neurotensin excitation of serotonergic neurons in the dorsal  
26 raphe nucleus of the rat in vitro. *The European journal of neuroscience*. 1996;8:153-61.  
27  
28

29  
30  
31 Jolicoeur FB, Gagne MA, Rivest R, Drumheller A, St-Pierre S. Atypical neuroleptic-like  
32 behavioral effects of neurotensin. *Brain research bulletin*. 1993;32:487-91.  
33  
34

35  
36  
37 Kitabgi P, Freychet P. Neurotensin contracts the guinea-pig longitudinal ileal smooth  
38 muscle by inducing acetylcholine release. *European journal of pharmacology*. 1979;56:403-6.  
39  
40

41  
42  
43 Kleczkowska P, Lipkowski AW. Neurotensin and neurotensin receptors: characteristic,  
44 structure-activity relationship and pain modulation--a review. *European journal of*  
45 *pharmacology*. 2013;716:54-60.  
46  
47

48  
49  
50 Kroner S, Rosenkranz JA, Grace AA, Barrionuevo G. Dopamine modulates excitability  
51 of basolateral amygdala neurons in vitro. *J Neurophysiol*. 2005;93:1598-610.  
52

53  
54  
55 Lantos TÁ, Palkovits M, Rostène W, Béroud A. Neurotensin receptors in the human  
56 amygdaloid complex. Topographical and quantitative autoradiographic study. *Journal of*  
57 *Chemical Neuroanatomy*. 1996;11:209-17.  
58  
59  
60  
61  
62  
63  
64  
65

1  
2  
3  
4 Lapchak PA, Araujo DM, Quirion R, Beaudet A. Neurotensin regulation of endogenous  
5  
6 acetylcholine release from rat striatal slices is independent of dopaminergic tone. Journal of  
7  
8 neurochemistry. 1991;56:651-7.  
9

10  
11 Maes M, Lin A-H, Bonaccorso S, Goossens F, Van Gastel A, Pioli R, et al. Higher serum  
12  
13 prollyl endopeptidase activity in patients with post-traumatic stress disorder. Journal of affective  
14  
15 disorders. 1999;53:27-34.  
16  
17

18  
19 Molewijk HE, van der Poel AM, Mos J, van der Heyden JA, Olivier B. Conditioned  
20  
21 ultrasonic distress vocalizations in adult male rats as a behavioural paradigm for screening anti-  
22  
23 panic drugs. Psychopharmacology. 1995;117:32-40.  
24  
25

26  
27 National Research Council Committee for the Update of the Guide for the Care and Use  
28  
29 of Laboratory Animals, Institute for Laboratory Animal Research, National Academies Press.  
30  
31 Guide for the care and use of laboratory animals. 8th ed. Washington, D.C.: National Academies  
32  
33 Press,; 2011. p. xxv, 220 p.  
34  
35

36  
37 Nemeroff CB. Neurotensin: perchance an endogenous neuroleptic? Biological psychiatry.  
38  
39 1980;15:283-302.  
40

41  
42 Paxinos G, Watson C. The rat brain in stereotaxic coordinates. 5th ed. Amsterdam ;  
43  
44 Boston: Elsevier Academic Press; 2005.  
45

46  
47 Petrie KA, Bubser M, Casey CD, Davis MD, Roth BL, Deutch AY. The neurotensin  
48  
49 agonist PD149163 increases Fos expression in the prefrontal cortex of the rat.  
50  
51 Neuropsychopharmacology. 2004;29:1878-88.  
52

53  
54 Prus AJ, Hillhouse TM, LaCrosse AL. Acute, but not repeated, administration of the  
55  
56 neurotensin NTS1 receptor agonist PD149163 decreases conditioned footshock-induced  
57  
58  
59  
60  
61  
62  
63  
64  
65

1  
2  
3  
4 ultrasonic vocalizations in rats. *Progress in neuro-psychopharmacology & biological psychiatry*.  
5  
6 2014;49:78-84.  
7

8  
9 Prus AJ, Huang M, Li Z, Dai J, Meltzer HY. The neurotensin analog NT69L enhances  
10 medial prefrontal cortical dopamine and acetylcholine efflux: Potentiation of risperidone-, but  
11 not haloperidol-, induced dopamine efflux. *Brain research*. 2007;1184:354-64.  
12  
13

14  
15 Rakovska A, Giovannini MG, Della Corte L, Kalfin R, Bianchi L, Pepeu G. Neurotensin  
16 modulation of acetylcholine and GABA release from the rat hippocampus: an in vivo  
17 microdialysis study. *Neurochemistry international*. 1998;33:335-40.  
18  
19

20  
21 Richard F, Barroso S, Martinez J, Labbe-Jullie C, Kitabgi P. Agonism, inverse agonism,  
22 and neutral antagonism at the constitutively active human neurotensin receptor 2. *Mol*  
23 *Pharmacol*. 2001;60:1392-8.  
24  
25

26  
27 Ruiz JS, Perera JLC, Hernanz A. Neuropeptidos plasmáticos en los trastornos afectivos y  
28 de ansiedad. *Archivos de Neurobiologica*. 1992;55:1-5.  
29  
30

31  
32 Sarret P, Perron A, Stroh T, Beaudet A. Immunohistochemical distribution of NTS2  
33 neurotensin receptors in the rat central nervous system. *J Comp Neurol*. 2003;461:520-38.  
34  
35

36  
37 Sánchez, C. Stress-induced vocalisation in adult animals. A valid model of anxiety? *Eur J*  
38 *Pharmacol*. 2003;463:133-143.  
39  
40

41  
42 Simola N. Rat ultrasonic vocalizations and behavioral neuropharmacology: from the  
43 screening of drugs to the study of disease. *Curr Neuropharmacol*. 2015;13:164-79.  
44  
45

46  
47 Szigethy E, Wenk GL, Beaudet A. Anatomical substrate for neurotensin-acetylcholine  
48 interactions in the rat basal forebrain. *Peptides*. 1988;9:1227-34.  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65



1  
2  
3  
4 Tyler BM, Douglas CL, Fauq A, Pang YP, Stewart JA, Cusack B, et al. In vitro binding  
5 and CNS effects of novel neurotensin agonists that cross the blood-brain barrier.  
6

7  
8  
9 Neuropharmacology. 1999;38:1027-34.  
10

11 Vincent JP, Mazella J, Kitabgi P. Neurotensin and neurotensin receptors. Trends  
12 Pharmacol Sci. 1999;20:302-9.  
13

14 Wustrow DJ, Davis MD, Akunne HC, Corbin AE, Wiley JN, Wise LD, et al. Reduced  
15 amide bond neurotensin 8-13 mimetics with potent in vivo activity. Bioorganic & Medicinal  
16 Chemistry Letters. 1995;5:997-1002.  
17  
18  
19  
20  
21  
22

23 Yamauchi R, Usui H, Yunden J, Takenaka Y, Tani F, Yoshikawa M. Characterization of  
24 beta-lactotensin, a bioactive peptide derived from bovine beta-lactoglobulin, as a neurotensin  
25 agonist. Biosci Biotechnol Biochem. 2003;67:940-3.  
26  
27  
28  
29  
30

31 Yamauchi R, Wada E, Kamichi S, Yamada D, Maeno H, Delawary M, et al. Neurotensin  
32 type 2 receptor is involved in fear memory in mice. Journal of neurochemistry. 2007;102:1669-  
33  
34  
35  
36  
37 76.

38 Yamauchi R, Wada E, Yamada D, Yoshikawa M, Wada K. Effect of beta-lactotensin on  
39 acute stress and fear memory. Peptides. 2006;27:3176-82.  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

**Figure Captions**

Figure 1. The effects of the neuropeptide neurotensin on USV calls in male Wistar rats (N=5). USV calls (means +/- SEM) refer to 22-kHz vocalizations. The abscissa refers to amounts of the compounds administered icv. \* P < 0.05 compared to 0.0 µg (i.e., vehicle).

Figure 2. The effects of the NTS<sub>1</sub> receptor agonist PD149163 (N=7) (top) and the NTS<sub>2</sub> receptor agonist JMV-431 (N=7) (bottom) on USV calls. \*\*\*P < 0.001 compared to 0.0 µg or 0.0 ng (i.e., vehicle). See figure 1 for further details.

Figure 1  
[Click here to download Figure: Figure 1.pdf](#)

# Neurotensin






Figure 2

[Click here to download Figure: Figure 2.pdf](#)

## PD149163



## JMV-431



**Table 1. Binding affinities for NTS<sub>1</sub> and NTS<sub>2</sub> receptors**

<b>Compound</b>	<b>NTS<sub>1</sub></b>	<b>NTS<sub>2</sub></b>	<b>Reference</b>
Neurotensin	0.2 nM (Kd)	4nM (Kd)	Vincent et al. 1999
PD149163	159 nM (Ki)	No affinity	Petrie et al. 2004
JMV-431	3315 nM (Ki)	38 nM (Ki)	Dubuc et al. 1999

**Table 2. USV call durations**

Compound	Dose	Mean (SEM) USV Call Duration (s)
Neurotensin	Vehicle	1.10 (0.12)
	0.1 µg	1.08 (0.14)
	1.0 µg	0.88 (0.15)
	10.0 µg	1.08 (0.05)
PD149163	Vehicle	1.14 (0.08)
	0.1 ng	1.15 (0.12)
	1.0 ng	1.09 (0.09)
	10.0 ng	1.02 (0.05)
JMV-431	Vehicle	1.12 (0.10)
	1.0 µg	1.09 (0.09)
	10.0 µg	0.95 (0.05)